Lonza Group stock ends the day lower at the close on the OTC market
Published on 09/21/2026 at 22:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group stock closed lower on the U.S. OTC market on September 21, 2026, underperforming a broadly mixed U.S. equity session. Compared with its recent home-market gains on SIX Swiss Exchange, the U.S.-listed shares lagged behind and finished the day below the level implied by today’s trading in Zurich.
September 21, 2026 in numbers
Lonza Group AG (ISIN CH0013841017) is primarily listed on SIX Swiss Exchange, where the shares advanced around 0.7 percent today, with intraday reports citing a price near 549.60 Swiss francs at the afternoon close of trading per Finanzen.ch. On the U.S. market, the OTC-traded Lonza Group ADRs closed in U.S. dollars below that home-market performance, reflecting both local sentiment and exchange-rate effects.
Per recent commentary on specialty pharma and contract manufacturing, Lonza continues to benefit from high-margin businesses, with its core EBITDA margin reportedly rising by 4.4 percentage points to 34.8 percent in the first half of 2026 and currency-adjusted revenue growing by 16 percent according to Finanzen.net. Despite this backdrop, today’s U.S. quote settled lower, while a large-cap U.S. healthcare peer and the S&P 500 index held steadier, underscoring Lonza’s relative weakness on the OTC listing.
After the bell and next trading day
After the close today, no major company-specific news or regulatory filings for Lonza Group were published in U.S. markets, and the ADRs saw only routine after-hours indications on the OTC venue. The next U.S. trading day is September 22, 2026, when investors will continue to watch broader healthcare and biotechnology peers for cues that could influence sentiment toward Lonza’s U.S.-listed shares. In Europe, Lonza’s home market on SIX Swiss Exchange will again set the tone earlier in the day before U.S. trading begins.
